Skip to main content

Mutz Christopher's Form 4 filing

Ani Pharmaceuticals IncANIP · filed Mar 6, 2024

Accession no.
0001846487-24-000008
Filed
Mar 6, 2024
Trade date
Mar 5, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $330.0K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mutz ChristopherCIK 0001846487Officer (HEAD OF RARE DISEASE)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 5, 2024Common StockSSaleDisposed−5,000$66.00F1−$330,00087,387Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were sold in multiple trades at prices ranging from $65.77 to $66.49. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)